消息指美团(03690.HK)配股及发可转债所得将大力投入科创、无人机配送等研发
早前据销售文件显示,美团 (03690.HK)计划配售约1.87亿股B类股份,每股配售价介乎265至274元,较前收市价折让约5.3%至8.4%,预期集资约68亿至70亿美元,另外公司亦将发行可转债。据消息人士指,美团此次筹得的资金将大力投入科技创新,用於对无人配送等科技研发及一般企业用途。
在最近一次业绩电话会议上,公司创办人兼首席执行官王兴就表达了对於前沿科技的关注,称前沿科技是美团关注的重点领域,并在电话会议上首次披露了美团无人配送的落地进展。疫情期间,美团在北京顺义区进行了无人配送的落地运营并成功完成了1.5万多个订单,还在深圳对美团无人机进行了空中配送测试。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.